Wolters Kluwer Health Completes Acquisition of Firecracker
March 21, 2018 - Wolters Kluwer Health announces today that it has completed the acquisition of Firecracker, as originally announced on March 5, 2018.
About Wolters Kluwer
Wolters Kluwer N.V. (AEX: WKL) is a global leader in information, software solutions, and services for professionals in the health, tax and accounting, risk and compliance, finance and legal sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.
Wolters Kluwer reported 2017 annual revenues of €4.4 billion. The company, headquartered in Alphen aan den Rijn, the Netherlands, serves customers in over 180 countries, maintains operations in over 40 countries, and employs 19,000 people worldwide.
Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).
For more information about our solutions and organization, visit www.wolterskluwer.com, follow us on Twitter, Facebook, LinkedIn, and YouTube.
| Media Annemarije Dérogée-Pikaar Global Brand & Communications t + 31 172 641 470 [email protected] Investors/Analysts Meg Geldens Investor Relations t + 31 172 641 407 [email protected] | Ann Joyal Global Brand & Communications, Health t + 1 781 392 3831 [email protected] |
Forward-looking Statements
This report contains forward-looking statements. These statements may be identified by words such as "expect", "should", "could", "shall" and similar expressions. Wolters Kluwer cautions that such forward-looking statements are qualified by certain risks and uncertainties that could cause actual results and events to differ materially from what is contemplated by the forward-looking statements. Factors which could cause actual results to differ from these forward-looking statements may include, without limitation, general economic conditions; conditions in the markets in which Wolters Kluwer is engaged; behavior of customers, suppliers, and competitors; technological developments; the implementation and execution of new ICT systems or outsourcing; and legal, tax, and regulatory rules affecting Wolters Kluwer's businesses, as well as risks related to mergers, acquisitions, and divestments. In addition, financial risks such as currency movements, interest rate fluctuations, liquidity, and credit risks could influence future results. The foregoing list of factors should not be construed as exhaustive. Wolters Kluwer disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Attachment:
http://www.globenewswire.com/NewsRoom/AttachmentNg/324ebd1c-eb8d-425e-9388-35a765e1f7d8


Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens
DeepSeek to Raise AI API Prices as Demand for New Models Surges
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results
Jetstar to Charge for Overhead Cabin Bags From February
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 



